IN2014DN09092A - - Google Patents
Info
- Publication number
- IN2014DN09092A IN2014DN09092A IN9092DEN2014A IN2014DN09092A IN 2014DN09092 A IN2014DN09092 A IN 2014DN09092A IN 9092DEN2014 A IN9092DEN2014 A IN 9092DEN2014A IN 2014DN09092 A IN2014DN09092 A IN 2014DN09092A
- Authority
- IN
- India
- Prior art keywords
- infarction
- medicinal composition
- treating
- active ingredient
- hsa mir
- Prior art date
Links
- 206010061216 Infarction Diseases 0.000 abstract 3
- 230000007574 infarction Effects 0.000 abstract 3
- 108091069002 Homo sapiens miR-145 stem-loop Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000004900 autophagic degradation Effects 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012090873 | 2012-04-12 | ||
| PCT/JP2013/061118 WO2013154192A1 (ja) | 2012-04-12 | 2013-04-12 | 梗塞治療用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09092A true IN2014DN09092A (pl) | 2015-05-22 |
Family
ID=49327750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9092DEN2014 IN2014DN09092A (pl) | 2012-04-12 | 2013-04-12 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150064237A1 (pl) |
| EP (1) | EP2837389A1 (pl) |
| JP (1) | JPWO2013154192A1 (pl) |
| KR (1) | KR20150002781A (pl) |
| CN (1) | CN104470543A (pl) |
| CA (1) | CA2870248A1 (pl) |
| IN (1) | IN2014DN09092A (pl) |
| WO (1) | WO2013154192A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7445997B2 (ja) | 2020-06-08 | 2024-03-08 | 国立大学法人東海国立大学機構 | マイクロrnaの慢性期心機能改善治療への利用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008539276A (ja) * | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
| CN102083980A (zh) * | 2008-02-21 | 2011-06-01 | 得克萨斯系统大学董事会 | 调节平滑肌增殖和分化的微小rna及其用途 |
| US8927506B2 (en) * | 2008-07-11 | 2015-01-06 | Board Of Regents, The University Of Texas System | Acetates of 2-deoxy monosaccharides with anticancer activity |
-
2013
- 2013-04-12 CN CN201380019601.0A patent/CN104470543A/zh active Pending
- 2013-04-12 KR KR20147031372A patent/KR20150002781A/ko not_active Withdrawn
- 2013-04-12 EP EP13776214.2A patent/EP2837389A1/en not_active Withdrawn
- 2013-04-12 CA CA 2870248 patent/CA2870248A1/en not_active Abandoned
- 2013-04-12 WO PCT/JP2013/061118 patent/WO2013154192A1/ja not_active Ceased
- 2013-04-12 US US14/391,302 patent/US20150064237A1/en not_active Abandoned
- 2013-04-12 IN IN9092DEN2014 patent/IN2014DN09092A/en unknown
- 2013-04-12 JP JP2014510217A patent/JPWO2013154192A1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104470543A (zh) | 2015-03-25 |
| JPWO2013154192A1 (ja) | 2015-12-21 |
| US20150064237A1 (en) | 2015-03-05 |
| WO2013154192A1 (ja) | 2013-10-17 |
| CA2870248A1 (en) | 2013-10-17 |
| KR20150002781A (ko) | 2015-01-07 |
| EP2837389A1 (en) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014062720A3 (en) | Methods of treating cancer | |
| WO2014152029A3 (en) | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| IN2014DN11099A (pl) | ||
| IN2015DN00376A (pl) | ||
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MY177994A (en) | Therapeutically active compounds and their methods of use | |
| IN2014DN10386A (pl) | ||
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| WO2016207090A3 (en) | Targeted conjugates of ksp inhibitors | |
| IL266623A (en) | A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer | |
| CA3292080A1 (en) | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| CA3010708A1 (en) | Methods of administering hepcidin | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| MY200803A (en) | Mpo inhibitors for use in medicine | |
| WO2015148971A3 (en) | Method for detecting or treating triple negative breast cancer | |
| WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents | |
| MX2020006228A (es) | Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas. | |
| GB2533235A (en) | Vesicles | |
| GEP20247606B (en) | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| IN2014DN09437A (pl) | ||
| HK1200731A1 (en) | Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy | |
| PT3937948T (pt) | Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares |